Collegium Sees Prelim. FY20 Xtampza ER Sales $150M-$160M, Sees Nucynta Franchise Revenues $170M-$180M

Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today provided full-year 2020 guidance for Xtampza® ER product revenues,

Benzinga · 01/07/2020 21:07

Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today provided full-year 2020 guidance for Xtampza® ER product revenues, Nucynta® franchise product revenues and total operating expenses.

“In 2020, Xtampza ER is well-positioned for the next stage of growth driven by the 15 new exclusive extended-release oxycodone formulary wins covering more than 35 million lives that took effect on January 1, 2020,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “Xtampza ER growth, as well as a commitment to leverage our existing cost structure, will drive Collegium to profitability in 2020.”

Financial Guidance for 2020

  • Xtampza ER revenues are expected in the range of $150.0 million to $160.0 million.
  • Nucynta franchise revenues are expected in the range of $170.0 million to $180.0 million.
  • Total operating expenses are expected in the range of $130.0 million to $140.0 million.